期刊文献+

厄洛替尼在肺外科围手术期中应用的实验研究

Experimental Study on Erlotinib in the Application for Pulmonary Surgery Perioperation
原文传递
导出
摘要 [目的]研究在肺外科围手术期中应用靶向药物的安全性、组织愈合情况及应用前景。[方法]行动物实验(实验狗)50只,术前3d、5d、7d及术后第1d起,口服厄洛替尼(特罗凯)每组各10只实验狗,观察毒副反应,对照组10只实验狗不服任何药物,二期手术切除支气管残端、肌肉、皮肤及皮下组织送病理检查。[结果]实验狗出现厌食90%,血尿10%。二期手术经病理检查术前3d服用厄洛替尼支气管残端愈合率70%,肌肉组织愈合50%,皮肤及皮下组织愈合率50%;术前5d服用厄洛替尼支气管残端愈合率80%,肌肉组织愈合率50%,皮肤及皮下组织愈合率50%;术前7d服用厄洛替尼支气管残端愈合率90%,肌肉组织愈合60%,皮肤及皮下组织愈合率60%;术后第1d服用厄洛替尼支气管残端愈合率80%,肌肉组织愈合40%,皮肤及皮下组织愈合率40%;对照组支气管残端愈合率80%,肌肉组织愈合率60%,皮肤及皮下组织愈合率60%。[结论]在外科围手术期中应用厄洛替尼毒性反应可耐受,不影响支气管愈合,有希望应用于临床实践。
机构地区 吉林省肿瘤医院
出处 《中国肿瘤》 CAS 2008年第12期1064-1066,共3页 China Cancer
  • 相关文献

参考文献5

  • 1吴一龙,廖美琳,周清华,无.非小细胞肺癌术后辅助治疗共识[J].循证医学,2004,4(4):236-238. 被引量:6
  • 2Tsuboi M,Ohira T, Saji H, et al. The present status of postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer [J]. Ann Thorac Cardiovasc Surg, 2007, 13(2):73-77.
  • 3Azzoli CG, Park B J, Pao W, et al. Molecularly tailored adjuvant chemotherapy for resected non-small cell lung cancer a time for excitement and equipoise[J]. J Thorac Oncol, 2008, 3( 1 ):84-93.
  • 4Solomon BJ, Rober H, Robert R, et al. Validation of proteomic classifier for clinical benefit from erlotinib as first line treatment for advanced non-small cell lung cancer (ECOG 3503). J Clin Oncol, 2007, 25:S7508.
  • 5Giaccone G, Gallegos Ruiz M, Le Chevalier T, et al. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase Ⅱ study[J]. Clin Cancer Res, 2006, 12 (20Pt 1) :6049 -6055.

二级参考文献15

  • 1[1]Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated individual patient data from 52 randomised clinical trials [J]. Br Med J, 1995, 311(7) :899-909.
  • 2[2]Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage Ⅰ , Ⅱ, or ⅢA non-small-cell lung cancer [J]. J Natl Cancer Inst, 2003,95(19): 1453-1461.
  • 3[3]The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer [J]. N Engl J Med, 2004, 350(4):351-360.
  • 4[4]Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung [J]. N Engl J Med, 2004, 350(17):1713-1721.
  • 5[6]Winton T, Livingston R, Johnson D, et al. A prospective randomized trial of adjuvant vinorelbine (VIN)and cisplatin (CIS) in completely resected stage IB and Ⅱ non-small cell lung cancer (NSCLC) Intergroup JBR 10 [C]. Proc Am Soc Clin Oncol, 2004, 23(suppl): 17. 7018a.
  • 6[7]Strauss G, Herndon J, Maddaus M, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB)Protocol 9633 [C]. Proc Am Soc Clin Oncol, 2004, 23(suppl):17. 7019a.
  • 7[8]Donker R, Stewart DJ, Dahrouge S, et al. Clinical characteristics and the impact of surgery and chemotherapy on survival of patients with advanced and metastatic bronchioloalveolar carcinoma: a retrospective study [J]. Clin Lung Cancer, 2000,1(3):211-215.
  • 8[9]Gandara DR, West H, Chansky K, et al. Bronchioloalveolar carcinoma: a model for investigating the biology of epidermal growth factor receptor inhibition [J]. Clin Cancer Res, 2004, 10(12): 4205s-4209s.
  • 9[10]Albain KS, Scott CB, Rusch VR, et al. Phase Ⅲ comparison of concurrent chemotherapy plus radiotherapy (CR/RT) and CT/RT followed by surgical resection for stage ⅢA(pN2) non-small cell lung cancer (NSCLC): initial results from intergroup trial 0139 (RTOG 93-09)[C]. Proc Am Soc Clin Oncol, 2003,22:621. 2497a.
  • 10[12]PORT Meta-analysis Trialists Group. Postoperative radiotherapy for non-small cell lung cancer (Cochrane Review). In: The Cochrane Library, Issue 1, 2001. Oxford: Update Software

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部